UnitedHealth Group Outlook - Street is trying to understand the next 6-18 months, with less focus on 2025 [2] - Expectation of reintroduced guidance from UnitedHealth with a new CEO [2] - Potential earnings range of $18-$20 for the balance of the year or fiscal year 2025 may be sufficient [3] - Previous expectations for UnitedHealth were closer to the high $20s, now trying to determine the trough earnings number [4] - Focus is on price discovery and investor multiple on future earnings (2026, 2027, etc) [4] Pharmaceutical Tariff Implications - Potential tariff angle on big pharma is being considered [1][5] - Street is bracing for a potential 15%-25% tariff rate across the board for large-cap pharma [7] - Sector-wide tariff has been rumored for 6-8 weeks with no concrete action [7] - Clarity on tariffs could lead to a rally in pharma stocks [8] - Uncertainty remains regarding the administration's actions and clarity on pharmaceutical policies [9] Pharmaceutical Industry Challenges - Focus on bringing pharmaceuticals back to America [6] - Potential impact of most favored nations status [9] - Losses of exclusivity are well-documented challenges [10]

Market Sentiment - Tariff uncertainty has subsided, contributing to market's climb near all-time highs [2] - Optimism in the markets is fueled by hopes of reaching deals and lower tariff levels than initially discussed [2] - Inflation appears to be trending in the right direction, although it has recently stagnated [2] Valuation and Earnings - S&P 500's PE ratio has surged past 23 [3] - Current earning seasons could set the path for the remainder of the year [3] Technical Indicators - Relative Strength Index (RSI) is used to assess whether a stock is overbought or oversold [1] - RSI has climbed above 70 several times recently, indicating overbought conditions [1]

Our next guest argues the markets have gotten too sanguin. For more, let's bring in Tom Hancock, portfolio manager at GMO. Uh Tom, great to have you with us.Why sanguin. Well, I think the market is, for example, on the tariff side, it's 15% tariff suddenly no big deal. This would have freaked people out back in March or you know, sort of deepse people have forgotten about and we see the risk trade back on whether it's AI names or crypto names.market hitting new highs every day last week and things aren't re ...

today. This just broke roughly about 45 minutes, maybe an hour ago, and it looks like the uh tariff situation is improving as Donald J. Trump met with I believe this is uh European Commission President Ursula Vanderlion nailed it and uh it's in the books and the uh tariff situation, the tariff trade between the US and the EU is there with 15% tariffs.And before we go on, just a little refresher for the Americans in the back, such as myself, and don't lie. Uh, if you're in a most of us don't know, we know of ...

A US trade court has for now denied an effort to restore a tariff exemption for small-value packages from China that Donald Trump ended earlier this year https://t.co/OLoYy9Ff5U ...

Bloomberg's David Gura is back with us now. So this 15% tariff rate, put that into perspective for us and what kind of impact we might see here at home. >> So we've seen the floor rise over the last few weeks.There was a lot of talk about being like a 10% floor for these tariffs. Then after Japan, it moved up to to 15. So again, it's significant because the baseline before this was so much lower, >> 1.2%.Right. >> Exactly. And so in the Europe's case, a little bit higher than that.But we've heard from compa ...

Welcome to Yahoo Finance's flagship show, The Morning Brief. I'm Julie Hyman. Let's get to the three things you need to know today.First up, US stock futures pushing higher this morning. That's after the US and European Union reached a trade deal. The EU will accept a 15% tariff on most of its exports to the US while reducing levies on some American products to zero.European Commission President Ursula Leander Lion hailed the agreement for the stability and predictability that it will offer businesses and c ...

💥BREAKING:🇺🇸 TRUMP SAYS “WE ARE GOING TO BE SETTING A TARIFF FOR THE REST OF THE WORLD AND THAT IS WHAT THEY HAVE TO PAY.” https://t.co/9sQA2tRMSR ...

It's going to bring us closer together. I think this deal will bring us very close together. Actually, >> it's a huge deal.Um, it will bring stability. It will bring predictability. That's very important for our businesses on both sides of the Atlantic.>> President Trump and the European Commission's President Ursula Bonderain said that we're looking at a 15% tariff on most European goods that are exported to the US. that crucially for the EU that includes the automotive sector uh which is something that th ...

Core Insights - Intuitive Surgical (ISRG) reported a second-quarter 2025 gross margin of 67.9%, down from 70% in the prior-year period, indicating structural shifts in operations and product mix [1][9] - The margin contraction is driven by the increasing contribution of newer, lower-margin platforms, particularly the da Vinci 5 and Ion systems, which have higher manufacturing and service costs [2][5] - Depreciation from recent capacity investments, including a new facility in Bulgaria, adds overhead costs, impacting short-term margins [3][9] - Tariff-related expenses reduced gross margin by approximately 60 basis points in Q2, with an expected annual drag of about 100 basis points [4][9] - Management anticipates long-term margin recovery through scale efficiencies and increased procedure volumes, despite near-term volatility [5][9] Peer Performance - Boston Scientific (BSX) reported an adjusted gross margin of 69.4%, down 100 basis points year over year, primarily due to inventory charges, but benefited from a favorable product mix [6] - Thermo Fisher (TMO) had an adjusted gross margin of 41.3%, down about 80 basis points, impacted by tariffs and foreign exchange, though productivity gains helped cushion the decline [7] Valuation and Estimates - ISRG shares have lost 5% year-to-date, compared to the industry's decline of 6.8% [8] - The forward price-to-earnings ratio for ISRG is 56.6, above the industry average but lower than its five-year median of 72.4 [11] - The Zacks Consensus Estimate for ISRG's 2025 earnings implies an 11.3% rise from the previous year [12]